The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart. In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here. The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.
Study Type
OBSERVATIONAL
Enrollment
11
Global longitudinal strain by echocardiography
Time frame: 6 months
Amount of late gadolinium enhancement by cardiac MRI
Time frame: 6 months
High-sensitivity troponin T
Time frame: 6 months
C-reactive protein
Time frame: 6 months
Serum NT-proBNP
Time frame: 6 months
Carboxyl-terminal telopeptide of collagen type I
Time frame: 6 months
Amino-terminal peptide of procollagen type III
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.